Compare TGE & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | TELA |
|---|---|---|
| Founded | 2023 | 2012 |
| Country | France | United States |
| Employees | 166 | 218 |
| Industry | Newspapers/Magazines | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.9M | 41.3M |
| IPO Year | N/A | 2019 |
| Metric | TGE | TELA |
|---|---|---|
| Price | $1.12 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 26.4K | ★ 209.5K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | $2.99 | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.78 | $0.50 |
| 52 Week High | $12.99 | $2.19 |
| Indicator | TGE | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 48.93 |
| Support Level | $1.02 | $0.59 |
| Resistance Level | $1.23 | $0.91 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 67.90 | 16.45 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.